Xue Gao

Xue Gao

Auto-generated profile, based on publicly available information

Xue Gao

Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA.

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Nature
Verified
Journal Article
Closed access
PDF file
JHJohnny H. Hu
Johnny H. Hu
SMShannon M. Miller
Shannon M. Miller
MGMaarten H. Geurts
Maarten H. Geurts
WTWeixin Tang
Weixin Tang
LCLiwei Chen
Liwei Chen
DLDavid R. Liu
David R. Liu

29 February 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MWMing Wang
Ming Wang
JZJohn A. Zuris
John A. Zuris
FMFantao Meng
Fantao Meng
HRHolly Rees
Holly Rees
SSShuo Sun
Shuo Sun
QXQiaobing Xu
Qiaobing Xu
Significance: The therapeutic potential of protein-based genome editing is dependent on the delivery of proteins to appropriate intracellular targets. Here we report that combining bioreducible lipid nanoparticles and negatively supercharged Cre recombinase or anionic Cas9:single-guide (sg)RNA complexes drives the self-assembly of nanoparticles for potent protein delivery and genome editing. The design of bioreducible lipids facilitates the degradation of nanoparticles inside cells in response to the reductive intracellular environment, enhancing the endosome escape of protein. In addition, modulation of protein charge through either genetic fusion of supercharged protein or complexation of Cas9 with its inherently anionic sgRNA allows highly efficient protein delivery and effective genome editing in mammalian cells and functional recombinase delivery in the rodent brain.

20 December 2017 in Nature
Verified
Journal Article
Closed access
PDF file
XGXue Gao
Xue Gao
YTYong Tao
Yong Tao
VLVeronica Lamas
Veronica Lamas
MHMingqian Huang
Mingqian Huang
WYWei-Hsi Yeh
Wei-Hsi Yeh
DLDavid R. Liu
David R. Liu

13 April 2014 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
GJGonzalo Jiménez-Osés
Gonzalo Jiménez-Osés
Sílvia OsunaSílvia Osuna
Sílvia Osuna
XGXue Gao
Xue Gao
MSMichael R Sawaya
Michael R Sawaya
LGLynne Gilson
Lynne Gilson
KHKendall N Houk
Kendall N Houk
Directed evolution of the final enzyme in the lovastatin biosynthetic pathway yields a variant with 29 mutations that does not require a carrier protein and displays altered dynamics of the catalytic residues, spending more time in the catalytically active conformation. Natural enzymes have evolved to perform their cellular functions under complex selective pressures, which often require their catalytic activities to be regulated by other proteins. We contrasted a natural enzyme, LovD, which acts on a protein-bound (LovF) acyl substrate, with a laboratory-generated variant that was transformed by directed evolution to accept instead a small free acyl thioester and no longer requires the acyl carrier protein. The resulting 29-mutant variant is 1,000-fold more efficient in the synthesis of the drug simvastatin than the wild-type LovD. This is to our knowledge the first nonpatent report of the enzyme currently used for the manufacture of simvastatin as well as the intermediate evolved variants. Crystal structures and microsecond-scale molecular dynamics simulations revealed the mechanism by which the laboratory-generated mutations free LovD from dependence on protein-protein interactions. Mutations markedly altered conformational dynamics of the catalytic residues, obviating the need for allosteric modulation by the acyl carrier LovF.

19 August 2012 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
XGXue Gao
Xue Gao
SHStuart W Haynes
Stuart W Haynes
BABrian D Ames
Brian D Ames
PWPeng Wang
Peng Wang
LVLinda P Vien
Linda P Vien
YTYi Tang
Yi Tang
The reconstitution of two fungal NRPSs provides the first biochemical evidence that these assembly lines use a condensation-like domain to complete the synthesis of cyclic natural products instead of the thioesterase domain used in bacterial species. Cyclization of linear peptidyl precursors produced by nonribosomal peptide synthetases (NRPSs) is an important step in the biosynthesis of bioactive cyclic peptides. Whereas bacterial NRPSs use thioesterase domains to perform the cyclization, fungal NRPSs have apparently evolved to use a different enzymatic route. In verified fungal NRPSs that produce macrocyclic peptides, each megasynthetase terminates with a condensation-like (CT) domain that may perform the macrocyclization reaction. To probe the role of such a CT domain, we reconstituted the activities of the Penicillium aethiopicum trimodular NPRS TqaA in Saccharomyces cerevisiae and in vitro. Together with the reconstituted bimodular NRPS AnaPS, we dissected the cyclization steps of TqaA in transforming the linear anthranilate-D-tryptophan-L-alanyl tripeptide into fumiquinazoline F. Extensive biochemical and mutational studies confirmed the essential role of the CT domain in catalyzing cyclization in a thiolation domain–dependent fashion. Our work provides evidence of a likely universal macrocyclization strategy used by fungal NRPSs.

7 February 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XGXue Gao
Xue Gao
YCYit-Heng Chooi
Yit-Heng Chooi
BABrian D. Ames
Brian D. Ames
PWPeng Wang
Peng Wang
CWChristopher T. Walsh
Christopher T. Walsh
YTYi Tang
Yi Tang